Funded Projects Chart 2020 - BioCanRx

X About BioCanRx Governance

Equity, Diversity & Inclusion Network Members and Investigators Our Team

X

Enabling Projects
Start Date	Project Title	Principle Investigator(s)	Total Project Funding
April 1, 2020	Enabling a Phase I/II multicenter clinical trial of a novel single domain (sd)CD22-specific camelid-derived chimeric antigen receptor (CAR) T-cell therapy	Kevin Hay, BC Cancer	BioCanRx funding: $450,000 Partner contributions: § BC Cancer Foundation $ 300,000 § National Research Council of Canada $200,000 (in-kind) Total Funding: $950,000
		Robert Holt, BC Cancer
		Brad Nelson, BC Cancer
July 1, 2020	Development of a virally programmed exosome-based cancer vaccine platform	Carolina Ilkow, The Ottawa Hospital Research Institute	BioCanRx funding: $616,500 Partner contributions: § Canadian Cancer Society $ 150,000 § McMaster University $60,000 § The Ottawa Hospital Research Institute $120,000 § Ontario Institute for Cancer Research $140,000 (cash & in-kind) § FACIT $1,045,000 (cash & in-kind) § Terry Fox Research Institute $180,000 Total Funding: $2,311,500
		Brian Lichty, McMaster University
		John Bell, The Ottawa Hospital Research Institute
July 1, 2020	First in human THINKK adoptive immuno-therapy to prevent leukemia and neuro-blastoma relapse: GMP-manufacturing and Phase I clinical trial initiation	Michel Duval, CHU Sainte-Justine	BioCanRx funding: $445,500 Partner contributions: § CHU Ste-Justine/Charles Bruneau Foundation $ 495,000 (cash & in-kind) Total Funding: $940,500
July 1, 2020	Development of Supporting Analytical Assays and Regulatory Compliance Package for Viral Sensitizer Technology Commercialization	Jean-Simon Diallo, Ottawa Hospital Research Institute	BioCanRx funding: $449,829 Partners: § TBA: $566,304 Total Funding: $1,016,133
		Christopher Boddy, University of Ottawa
		Jeffrey Smith, Carleton University
October 1, 2020	Clinical Trial Enabling Studies for Multi-targeted Chimeric Antigen Receptor Therapeutics for the treatment of B-Cell Malignancies	Scott McComb, National Research Council of Canada/ University of Ottawa	BioCanRx funding: $450,000 Partners: § BC Cancer Foundation $200,000 (in-kind) § TBA $300,000 Total Funding: $950,000
		Natasha Kekre, Ottawa Hospital Research Institute
		Robert Holt, BC Cancer
		John Webb, BC Cancer
		Kevin Hay, BC Cancer
October 1, 2020	Recombinant TCRs to target KRAS hotspot mutations in pancreatic cancer	Robert Holt, BC Cancer	BioCanRx funding: $450,000 Partner contributions: § BC Cancer Foundation $ 480,000 § Chaire Roger Des Groseillers d’oncologie chirurgicale hépato-biliaire et pancréatique de l’Université de Montréal $20,000 Total Funding: $950,000
		Simon Turcotte, Université de Montréal

Clinical, Social, & Economic Impact (CSEI) Projects
Start Date	Project Title	Principle Investigator(s)	Total Project Funding
March 26, 2019	Using real-world data and iterative economic evaluation to prioritize resource allocation for care and research in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia ***	Kednapa Thavorn, The Ottawa Hospital Research Institute	BioCanRx funding: $100,000 Partner contributions: § Ontario Institute for Cancer Research $184,955 § ICES § Ottawa Methods Centre § The Ottawa Hospital Research Institute Total Funding: $284,955
		Harry Atkins, The Ottawa Hospital Research Institute
		Natasha Kekre, The Ottawa Hospital Research Institute
April 1, 2019	Assessing the Real-World Clinical and Economic Outcomes of Emerging Innovative Technologies in Oncology: The Cases of Biosimilars and CAR T-cells ***	Kelvin Chan, Sunnybrook Research Institute	BioCanRx funding: $100,000 Partner contributions: § Ontario Institute for Cancer Research $197,217 § Ontario Health (Cancer Care Ontario) $40,540 (in-kind) § Canadian Centre for Applied Research in Cancer Control $11,160 (in-kind) Total Funding: $348,917
		Scott Gavura, Ontario Health
		Wanrudee Isaranuwatchai, Unity Health
July 1, 2020	Identifying effect modifiers for CAR-T cell therapeutic efficacy	Dean Fergusson, The Ottawa Hospital Research Institute	BioCanRx funding: $100,058 Partner contributions: § Ottawa Methods Centre $50,000 (in-kind) § Cell Therapy Transplant Canada $10,000 (in-kind) § Leukemia & Lymphoma Society of Canada $10,000 (in-kind) § BLUEPRINT Translational Research Group $10,000 (in-kind) § National Research Council of Canada $10,000 (in-kind) Total Funding: $190,058
October 1, 2020	Making Patient Partnerships A Reality in Very Early Phase Clinical Trials (MARVEL): Development of a Patient Engagement Platform	Manoj Lalu, The Ottawa Hospital Research Institute	BioCanRx funding: $361,490 Partners: § TBA Total Funding: $361,490
		Dean Fergusson, The Ottawa Hospital Research Institute
		Justin Presseau, The Ottawa Hospital Research Institute

*** The funding for these projects was announced on an earlier date.

Clinical Trial Projects
Start Date	Project Title	Principle Investigator(s)	Total Project Funding
April 1, 2020	COV-IMMUNO- A randomized phase III trial of vaccination with IMM-101 versus observation for the prevention of serious respiratory and COVID-19 related infections in cancer patients ***	Rebecca Auer, The Ottawa Hospital	BioCanRx funding: $750,000 Partner contributions: § Immodulon Therapeutics $400,000 (in-kind) § Canadian Centre for Applied Research in Cancer Control $50,000 § The Ottawa Hospital Foundation $25,000 § Ontario Institute for Cancer Research (OICR) $100,000 (in-kind) § The Ottawa Hospital Academic Medical Organization $96,000 § ATGen $44,500 (in-kind) § Canadian Cancer Trials Group (CCTG)/ Canadian Cancer Society $1,368,611 (cash + in-kind) Total Funding: $2,834,111
April 1, 2020		Christopher O’Callaghan, Queen’s University
April 1, 2020	Phase II CYTOSHRINK Trial: Cytoreductive Stereotactic Hypofractionated Radiotherapy with Combination Ipilimumab and Nivolumab for Metastatic Kidney Cancer	Aly-Khan Lalani, McMaster University	BioCanRx funding: $489,872 Partner contributions: § Bristol-Myers Squibb $774,349 § Ontario Clinical Oncology Group $77,435 (cash & in-kind) Total Funding: $1,341,656
		Jonathan Bramson, McMaster University
		Michael Surette, McMaster University
October 1, 2020	The Selected Tumor-infiltrating lymphocyte Against Refractory Melanoma-01 Trial (STAR-M01)	Simon Turcotte, Centre hospitalier de l’Université de Montréal	BioCanRx funding: $675,000 Total partner funding: $2,305,850 § Iovance Biotherapeutics § Institut du cancer de Montréal § Centre de Recherche du Centre Hospitalier de l’Université de Montréal/ Centre Hospitalier de l’Université de Montréal § Héma-Québec § Canada Research Chair in Patient and Public Partnership Total Funding: $2,980,850
October 1, 2020	An interventional, open-label, nonrandomized dose-escalation Phase I multicenter clinical trial of multi-peptide anti-minor histocompatibility antigen immunotherapy for the prevention of relapse in patients with high-risk malignancy eligible for matched related ASCT	Denis Claude Roy, Hôpital Maisonneuve-Rosemont	BioCanRx funding: $675,000 Partner contributions: § HMR-CIUSSS-East-of-Montreal $800,000 § CellCAN $20,000 § C3i $100,000 (in-kind) Total Funding: $1,595,000

*** The funding for these projects was announced on an earlier date.

Core & Biomanufacturing Facilities
CORE FACILITIES
Start Date	Project Title	Principle Investigator(s)	Total Project Funding
April 1, 2020	Molecular & Cellular Immunology Core (MCIC), BC Cancer Deeley Research Centre	Brad Nelson, BC Cancer	BioCanRx funding: $300,000
July 1, 2020	Human Immune Testing Suite (McMaster University)	Jonathan Bramson, McMaster University	BioCanRx funding: $283,366
BIOMANUFACTURING FACILITIES
September 1, 2020	Alberta Cell Therapy Manufacturing Centre	Gregory Korbutt, University of Alberta	BioCanRx funding: $3,391,004 Partner contributions: § TBA: $4,499,380 Total Funding: $7,890,384
September 1, 2020	Conconi Family Immunotherapy Lab	Brad Nelson, BC Cancer
September 1, 2020	Conconi Family Immunotherapy Lab	John Webb, BC Cancer
September 1, 2020	The Ottawa Hospital Biotherapeutics Manufacturing Centre	John Bell, The Ottawa Hospital Research Institute
October 31, 2020	Three New Point-of-Care Manufacturing Sites; locations TBA	TBA